Drug Topics
NOVEMBER 5, 2024
Erin Rexroth, director of marketing at NCPA, discusses how smaller pharmacies can compete with large chains when it comes to digital marketing.
STAT
NOVEMBER 5, 2024
A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing. Beam said the patient succumbed to respiratory failure, deemed to be “likely caused” by a regimen of chemotherapy required to prepare the patient for BEAM-101, a treatment that uses the company’s new, more precise form of CRISPR gene editing called base editing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
NOVEMBER 5, 2024
A conversation with Lauren Angelo, PharmD, MBA, associate dean of academic affairs and an associate professor of pharmacy practice at Rosalind Franklin University of Medicine and Science College of Pharmacy.
STAT
NOVEMBER 5, 2024
In a viral TikTok, a woman in the emergency room shares a message questioning why so many women in their 30s struggle with cancer and infertility, and suggests that birth control’s long-term hormonal disruption is the cause. Another influencer mocks the FDA inserts that accompany birth control, unfolding the long lists of side effects in videos to humorously repurpose them as “blankets” for napping or as tools for helping men grasp the harsh realities their partners face to
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
NOVEMBER 5, 2024
A collection of independent pharmacies was the next in line to file suits against major pharmacy benefit managers for alleged drug price fixing.
Pharmacy Times
NOVEMBER 5, 2024
Using in vitro models, study investigators predict the risk of bone metastasis in breast cancer based on correlations with their in vivo behaviors and potential.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
NOVEMBER 5, 2024
“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.
STAT
NOVEMBER 5, 2024
When this year’s Nobel Prize in chemistry went to three scientists for their work in protein structure prediction and design, the decision was indicative of a zeitgeist in biotech. “[A] dream of scientists has been to build new proteins, to learn how to use nature’s multitool for our own purposes … opening endless possibilities for the greatest benefit to humankind,” Heiner Linke, chair of the Nobel Prize committee for chemistry, said while announci
pharmaphorum
NOVEMBER 5, 2024
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.Shares in the company gained almost 24% after it announced that the end of phase 2 meeting with the US regulator had firmed up plans for a phase 3 trial of bitopertin in EPP, as well as the potential for accelerated approval.
STAT
NOVEMBER 5, 2024
Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial nerve palsies, according to early results from a Phase 3 clinical trial reported Tuesday. While still preliminary, the benign neurotoxicity assessment for the therapy, called anito-cel, suggests it could be a safer option for patients with multiple myeloma compared to Carvytki, a currently approved CA
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
NOVEMBER 5, 2024
Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial.
STAT
NOVEMBER 5, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. Hope everyone takes it easy in what will be a long day today. Now let’s get into the biotech news.
Pharmacy Times
NOVEMBER 5, 2024
Less than 16% of high-risk lung cancer individuals have heard or discussed lung cancer screenings with a health care provider.
pharmaphorum
NOVEMBER 5, 2024
AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest market, wiping around $14 billion off its value.The sell-off appears to have been prompted by an article in Chinese financial media outlet Yicai which suggested that "dozens of senior executives" at AZ's Chinese subsidiary have been implicated in an ongoing insurance fraud case.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
NOVEMBER 5, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Election Day is finally here. What to say? If you’re feeling at all grateful for STAT’s journalism today, consider supporting our newsroom. We’re currently offering 40% off our annual subscription.
Fierce Pharma
NOVEMBER 5, 2024
With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta thalassemia, “there has never been a more exciting time to be at Vertex,” c | With its first Casgevy revenues in the books, Vertex lifted its full-year sales outlook as it turns its attention to two product launches in 2025, including an expected new entrant in the pain market.
Pharmacy Times
NOVEMBER 5, 2024
Kristi Veis discusses the importance of flu vaccinations and the role of pharmacists in administering them.
pharmaphorum
NOVEMBER 5, 2024
Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high. In today’s podcast, web editor Nicole Raleigh speaks with Dr Neal Kassell, chair and founder of the Focused Ultrasound Foundation and previously a neurosurgeon, who created the Foundation in 2006 to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ult
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
NOVEMBER 5, 2024
Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for geographic atrophy (GA), Syfovre, may have hit a performance “nadir” in 2024 | Over the latest earnings stretch, Apellis' Syfovre saw sales down about 2% from the previous quarter despite an overall demand increase of about 7%.
pharmaphorum
NOVEMBER 5, 2024
Beam shines a light on phase 1/2 data with its base editing candidate for sickle cell disease ahead of a full presentation at ASH next month
Drug Topics
NOVEMBER 5, 2024
Companies like ShiftRx are using technology to help solve the staffing shortage crisis in health care.
The Guardian - Pharmaceutical Industry
NOVEMBER 5, 2024
Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price AstraZeneca shares tumbled on Tuesday wiping £14bn off the value of Britain’s biggest drug maker, after a report that dozens of senior executives at its China unit could be implicated in an insurance fraud case in the country’s pharmaceutical sector. Also putting pressure on the share price, early data on AstraZeneca’s experimental weight loss pill published on Monday was described as “somewhat un
STAT
NOVEMBER 5, 2024
Every few decades the United States launches a big science project. The original “moon shot” was kicked off by NASA’s Apollo Program in the 1960s. Its spiritual successor, the Human Genome Project, was launched in 1990 and concluded a dozen years later with the first sequenced genome. In 2016, the Cancer Moonshot debuted. Now is time for the next moon shot.
Drug Topics
NOVEMBER 5, 2024
The drug is also approved to treat schizophrenia and bipolar depression.
Fierce Pharma
NOVEMBER 5, 2024
With its first FDA approval coming in August and a sec | With its first FDA approval coming in August and a second expected next month, these are exhilarating days for 19-year-old Syndax Pharmaceuticals as it transforms into a commercial enterprise. To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million deal with Royalty Pharma.
PioneerRx
NOVEMBER 5, 2024
Well, here we are: November, only two months until we welcome in the new year. As this year draws to a close, the last two months offer a powerful opportunity to.
pharmaphorum
NOVEMBER 5, 2024
Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.The new capsule formulation of the antibiotic minocycline hydrochloride has been cleared by the US regulator to treat the inflammatory lesions caused by rosacea – which causes flushing or long-term redness and pustules on the face – in adults.
Outsourcing Pharma
NOVEMBER 5, 2024
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and obese adults with heart disease.
PharmaVoice
NOVEMBER 5, 2024
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
STAT
NOVEMBER 5, 2024
Good morning, everyone, and how are you today? We are doing just fine, thank you, despite cloudy skies looming over the Pharmalot campus. After all, the birds are still chirping and crisp autumn breezes are wafting by. Moreover, this is an exciting day on this side of the pond, where millions of voters are casting their ballots in hopes of changing their world.
Fierce Pharma
NOVEMBER 5, 2024
As the U.K. works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. | Flush with a 50 million pound sterling ($65 million) joint investment deal from the U.K., Accord—one of Europe's top makers of generic chemotherapies—is embarking on an expansion of its Fawdon drug manufacturing facility in Newcastle upon Tyne, England.
Pharmacy Times
NOVEMBER 5, 2024
About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.
STAT
NOVEMBER 5, 2024
Tuesday’s oral arguments before the Supreme Court in a case involving billions in Medicare payments to hospitals revealed a split among the justices willing to show their cards. The case, Advocate Christ Medical Center v. Becerra, concerns Medicare payments to safety net hospitals, known as disproportionate share hospital, or DSH, payments, which are designed to compensate them for treating low-income patients.
Expert insights. Personalized for you.
179 
Let's personalize your content